Ironwood Pharmaceuticals vs Phathom Pharmaceuticals
IRWD and PHAT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRWD and PHAT compare
Ironwood Pharmaceuticals is the larger company, worth 1.6 times as much as Phathom Pharmaceuticals ($801M against $493M).
Phathom Pharmaceuticals grew revenue faster over the last twelve months (86.8% versus 18.1% for Ironwood Pharmaceuticals).
Ironwood Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 37.4% compared with −30.2% at Phathom Pharmaceuticals.
Ironwood Pharmaceuticals scores higher on the StockData Score (13 against 4 for Phathom Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRWD | PHAT |
|---|---|---|
| Size and price | ||
| Market cap | $801M | $493M |
| Share price | $4.85 | $6.06 |
| Change, 1 year | 67.8% | −58.5% |
| Change, 5 years | −58.5% | −69.8% |
| Beta (5Y) | 0.56 | 1.63 |
| Employees | 100 | 371 |
| StockData Score | ||
| Total score | 13 (better) | 4 |
| Valuation score | 6 (better) | 1 |
| Growth score | 3 (better) | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 5.4× | – |
| P/S | 2.0× | 1.8× (better) |
| EV/EBITDA | 2.8× | – |
| FCF yield | – | −4.3% |
| Fair value | $15.55 | – |
| Margin of safety | 68.8% | – |
| Growth | ||
| Revenue growth (TTM) | 18.1% | 86.8% (better) |
| Revenue growth, 5Y average | −5.3% | – |
| Net income growth (TTM) | 424% | – |
| EPS growth (TTM) | 500% | – |
| EPS growth, 5Y average | −25.6% | – |
| Profitability | ||
| Gross margin | – | 80.7% |
| Operating margin | 62.9% (better) | −9.3% |
| Net margin | 37.4% (better) | −30.2% |
| FCF margin | – | −7.7% |
| Financial health | ||
| Interest coverage | 8.3× (better) | −0.4× |
| Current ratio | 6.51 (better) | 1.76 |
| Altman Z-score | −1.06 (better) | −4.83 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.2% | 88.7% |
| Held by insiders | 16.0% | 12.2% |
| Insider net buying, 12 months | −$22.6M | $0 (better) |
| Short interest, % of float | 10.7% | 12.9% |
Go deeper
- IRWD stock overview
- IRWD income statement
- IRWD valuation and score
- PHAT stock overview
- PHAT income statement
- PHAT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.